Use of sugammadex to reverse moderate to deep neuromuscular blockade.

Efficacy of different doses of sugammadex for antagonism of neuromuscular blockade in patients pre-treated with intravenous magnesium sulphate -A Randomised Controlled Study - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069838

Enrollment

Registered

2024-07-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: SUGAMMADEX: One group of Patients will recieve 4mg/kg of drug. Another group of patients will recieve 8mg/kg of drug.time taken to reach TOF 0.9 after injection of reversal. Interventio

Eligibility

Inclusion criteria

Inclusion criteria: Age 18-65 years American Society Of Anaesthesiologists(ASA)physical status I-II Patients scheduled to undergo laparoscopic surgeries

Exclusion criteria

Exclusion criteria: 1.Subjects with coagulopathy and bleeding disorders 2.Predicted difficult airway 3.obese patients 4.Subjects with cardiac disease 5.Subjects with neuromuscular disease

Design outcomes

Primary

Measure	Time frame
Time to reach TOF ratio 0.9 after injection of sugammadex at the time of extubationTimepoint: Baseline	—

Secondary

Measure	Time frame
1)SBP(mmHg),DBP(mmHg),HR at10,30,60,90 minutesafter intubation 2)Amount of propofol consumed in mg/kgTimepoint: 10,30,60,90 minutes post intubation 24hrs post intubation	—

Countries

India

Contacts

Public ContactDr Prof Ganesh Chandra Satapathy

Kalinga institute of medical sciences

ganesh.satapathy@kims.ac.in8283872939

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026